What is Scopio?
Scopio Labs is fundamentally transforming the landscape of cell morphology analysis by bridging the gap between traditional microscopy and modern digital workflows. By deploying a suite of fully digital diagnostic applications, the company enables laboratories to overcome the historical trade-off between field-of-view and resolution. Its FDA-cleared and CE-marked platforms, including the Full-Field Peripheral Blood Smear application and the ScopioVet veterinary solution, provide clinicians with unprecedented depth and consistency. By integrating AI-powered decision support systems, Scopio facilitates faster, more accurate disease detection, ultimately expediting patient access to life-saving treatments across the continuum of care.
How much funding has Scopio raised?
Scopio has raised a total of $118M across 3 funding rounds:
Series B
$16M
Series C
$50M
Series D
$52M
Series B (2020): $16M with participation from Aurum Ventures Private, Olive Tree Ventures, OurCrowd, and LR group
Series C (2022): $50M led by Aurum, Ilex Medical, Bank Mizrahi-Tefahot, and OurCrowd
Series D (2025): $52M supported by Viola Group and Fortissimo
Key Investors in Scopio
Viola Group
Viola Group is a premier Israeli technology investment firm managing over $6 billion in assets, dedicated to supporting transformational companies through a multi-strategy approach across various growth stages.
Fortissimo
Fortissimo Capital is a leading private equity fund specializing in technology and industrial sectors, known for its proactive approach to facilitating sustainable growth and operational success.
Aurum
Aurum Ventures MKI is a technology-focused investment arm that targets innovation in communication, media, and information sectors, backed by a legacy of supporting industry-leading enterprises.
What's next for Scopio?
With the successful closure of this major enterprise-level funding round, Scopio is positioned to accelerate its commercial expansion across the United States and Europe. The strategic focus will likely shift toward deepening the integration of its AI-driven diagnostic tools within existing hospital infrastructure and expanding its product portfolio to address additional clinical pathologies. By leveraging this recent capital, the company aims to solidify its market position as the standard-bearer for digital cell morphology, ensuring that high-resolution, automated diagnostic capabilities become the baseline for efficient and consistent laboratory operations worldwide.
See full Scopio company page
